FOLH1 and metastatic malignant neoplasm: Similarly, VEE replicons expressing the prostate-specific membrane antigen (PSMA) were applied for a human trial of patients with metastatic cancers at five doses of 0.9 × 107 IU or 3.6 × 107 IU [99].